Panobacumab

帕诺库单抗

Report date: 2025/01/14 20:00:08

Base Information

Drug NamePanobacumab
Drug Alias NameAR-101AERUMAB-11KBPA-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLipopolysaccharide (LPS) inhibitors
TargetsLipopolysaccharide (LPS)
Therapy Area/IndicationsPneumoniaPneumonia, Ventilator-Associated
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBerna Biotech LtdAridis Pharmaceuticals IncKenta Biotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKenta Biotech LtdShenzhen Hepalink Pharmaceutical Group Co Ltd
Active IndicationsN/A
Inactive IndicationsPneumoniaPneumonia, Ventilator-Associated

Other Information

ATC CodeN/A
Related LinksWikipedia